Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
LivaNova PLC (DE:LIA)
FRANKFURT:LIA
LivaNova (LIA) Stock Price & Analysis
1 Followers
LIA Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€39.20 - €53.50
Previous Close€48.6
Volume0.00
Average Volume (3M)5.00
Market Cap
€2.65B
Enterprise Value€2.99B
Total Cash (Recent Filing)$266.50M
Total Debt (Recent Filing)$632.04M
Price to Earnings (P/E)N/A
Beta0.65
Next Earnings
May 01, 2024EPS Estimate
€0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding53,956,158
10 Day Avg. Volume0
30 Day Avg. Volume5
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)12.09
Price to Sales (P/S)2.27
Price to Cash Flow (P/CF)13.10
P/FCF Ratio12.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.59
Enterprise Value/Gross Profit3.88
Enterprise Value/Ebitda51.98
Forecast
1Y Price Target
€63.08Price Target Upside29.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
LivaNova News
PremiumCompany Announcements
LivaNova Prices $300M Convertible Notes, Secures Capped Calls
PremiumCompany Announcements
LivaNova PLC Announces $300M Convertible Notes Offering
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessLIVN announced a positive predictive outcome with its OSPREY clinical trial of its aura600 hypoglossal nerve stimulation device for obstructive sleep apnea.
Financial PerformanceLivaNova's Q4 revenues and adjusted EPS beat expectations, indicating stronger financial performance than anticipated.
Market OpportunityThe obstructive sleep apnea market is very large, with an estimated 54M people in the US suffering from the condition, presenting a significant market opportunity for LIVN's aura6000.
Bears Say
Management CredibilityLong-term risk/reward attractiveness limited by lack of confidence in management's growth direction and need to reverse operating margin declines.
Operational PerformanceDespite positive earnings, LivaNova's gross margins and operating margins came in below expectations, which could be a concern for profitability.
ValuationDespite increased sales and EPS estimates, the target multiple has been reduced, aligning more with the stock's current and historical trading multiple.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.49% Other Institutional Investors
99.51% Public Companies and
Individual Investors
LIA FAQ
What was LivaNova PLC’s price range in the past 12 months?
LivaNova PLC lowest stock price was €39.20 and its highest was €53.50 in the past 12 months.
What is LivaNova PLC’s market cap?
Currently, no data Available
When is LivaNova PLC’s upcoming earnings report date?
LivaNova PLC’s upcoming earnings report date is May 01, 2024 which is in 6 days.
How were LivaNova PLC’s earnings last quarter?
LivaNova PLC released its earnings results on Feb 21, 2024. The company reported €0.816 earnings per share for the quarter, beating the consensus estimate of €0.722 by €0.094.
Is LivaNova PLC overvalued?
According to Wall Street analysts LivaNova PLC’s price is currently Undervalued.
Does LivaNova PLC pay dividends?
LivaNova PLC does not currently pay dividends.
What is LivaNova PLC’s EPS estimate?
LivaNova PLC’s EPS estimate is €0.46.
How many shares outstanding does LivaNova PLC have?
Currently, no data Available
What happened to LivaNova PLC’s price movement after its last earnings report?
LivaNova PLC reported an EPS of €0.816 in its last earnings report, beating expectations of €0.722. Following the earnings report the stock price went up 5.263%.
Which hedge fund is a major shareholder of LivaNova PLC?
Among the largest hedge funds holding LivaNova PLC’s share is PRIMECAP Management Co. It holds LivaNova PLC’s shares valued at 300M.
---
LivaNova Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€63.08 (29.80% Upside)
€63.08 (29.80% Upside)
Blogger Sentiment
Neutral
DE:LIA Sentiment 50%
Sector Average 69%
Sector Average 69%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.75%
12-Months-Change
Fundamentals
Return on Equity
1.41%
Trailing 12-Months
Asset Growth
5.87%
Trailing 12-Months
Company Description
LivaNova PLC
LivaNova Plc is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the following segments: Cardiovascular, Neuromodulation, and Others. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and advanced circulatory support products. The Neuromodulation segment designs and markets NM-based medical devices for the treatment of epilepsy, depression, and obstructive sleep apnea. The Other segment consists of company's shared service expenses for finance, legal, human resources, information technology, and new ventures. Its products include VNS therapy system. oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, and cannulae. The company was founded on February 20, 2015 and is headquartered in London, the United Kingdom.
---
LIA Company Deck
---
LIA Earnings Call
Q4 2024
0:00 / 0:00
---
LIA Stock 12 Months Forecast
Average Price Target
€63.08
▲(29.80% Upside)
Technical Analysis
HeartBeam
―
Edwards Lifesciences
―
Smith & Nephew Snats
―
Boston Scientific
―
LivaNova
―
Best Analysts Covering LIA
1 Year
1 Year Success Rate
10/20 ratings generated profit
1 Year Average Return
-2.93%
reiterated a buy rating last month
Copying Michael Matson's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -2.93% per trade.
---